In this analysis, we tested the hypothesis that early, more complete RAAS inhibition would result in a graded reduction in aldosterone concentrations after ACS in patients without heart failure or LVSD
, a group in which a benefit ofinhibition ofRAAS remains uncertain.
Patients age 18 and older with LVSD
heart failure defined by the International Classification of Diseases, ninth revision (ICD-9-CM) codes 402.
A normal ECG in suspected heart failure patients does not reliably rule out mild LVSD
," she added.
, CoQ10 also significantly decreases lactate/pyruvate ratio.
Provide timely ECG readings and interpretations in the annual assessment of people with LVSD
(on the QoF register).
1]/forced vital capacity ratio; LVEF, left ventricular ejection fraction; LVSD
, LV systolic dysfunction; LVH, LV hypertrophy; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
In a pre-specified analysis of the landmark EPHESUS(TM) (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) clinical trial, eplerenone, compared to placebo, significantly reduced deaths by at least 31 percent above and beyond standard therapy within 30 days of starting treatment in patients who had a heart attack complicated by LVSD
and heart failure.
In Ephesus, heart attack patients with LVSD
and heart failure on standard therapy, including angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) and beta-blockers, were randomized 3 to 14 days post-heart attack to receive eplerenone 25 mg once daily (n=3319) or placebo (n=3313).
Heart Attack Care: who receive Aspirin at Arrival, Aspirin at Discharge, ACE Inhibitor for LVSD
, Beta Blocker at Arrival, Beta Blocker at Discharge, Thrombolytic Agent Received, PTCA Received and Adult Smoking Cessation Advice.
The new guidelines are based in part on the landmark Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS(TM)), which demonstrated significant survival and hospitalization benefits with the use of the selective aldosterone blocker INSPRA(R) (eplerenone) in addition to current standard therapy in heart attack patients with evidence of LVSD
and heart failure after a heart attack.
The use of Amias for the treatment of CHF with LVSD
results in longer lives for patients with this debilitating condition and patients will require significantly fewer hospitalisations due to exacerbations of their heart failure.
Similarly, values for LAD, LVDD, LVSD
, interventricular septum thickness (IVST) and left ventricular posterior wall thickness (LVPWT) were significantly higher in obese patients than their healthy counterparts (p<0.